Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: A California cancer consortium trial

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 5, 2002, Pages 353-359

  Yen, Yun ^a   Chow, Warren ^a   Leong, Lucille ^a   Margolin, Kim ^a   Morgan, Robert ^a   Raschko, James ^a   Shibata, Stephen ^a   Somlo, George ^a   Twardowski, Przemyslaw ^a   Frankel, Paul ^a   Longmate, Jeff ^a   Synold, Timothy ^a   Newman, Edward M ^a   Lenz, Heinz Josef ^b   Gandara, David ^c   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug sequence; Gemcitabine; Hydroxyurea; Ribonucleotide reductase

Indexed keywords

GEMCITABINE; HYDROXYUREA;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS TUMOR; FEMALE; GALLBLADDER TUMOR; GERM CELL TUMOR; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; LUNG TUMOR; MALE; OVARY TUMOR; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; STOMACH TUMOR; THYROID TUMOR; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; CALIFORNIA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HEPATITIS, TOXIC; HUMANS; HYDROXYUREA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 0036453259     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0492-9     Document Type: Article

References (38)

1. Burchenal JH, Leyland-Jones B, Watanabe K, Klein R, Lopez C, Fox JJ (1983) Experimental and clinical studies of 2′-fluoroarabinosyl-pyrimidines and purine-like C-nucleosides. In: Proceeding of the Fifth International Roundtable on Nucleosides, Nucleotides, and Their Biological Applications. Academic Press, New York, pp 47-65
2. Herte LW, Kroin JS, Misner JW, Tustin JM (1988) Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2′2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406-2409
3. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422
4. Plunkett W, Gandhi V, Chubb J, Nowak B, Heinmann V, Mineishi S, Sen A, Hertel LW, Grindey GB (1989) 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action on human leukemia cells. Nucleosides Nucleotides 8:775-785
5. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
6. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′-2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024-4301
7. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel W, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572
8. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ, Lippert B, Jarvi E, Resvick R (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 57prime;-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879-1884
9. Cory JG, Carter GL (1988) Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cancer Res 48:839-843
10. Arver ESJ, Spasokoukotskaja T, Eriksson S (1992) Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem Biophys Res Commun 188:712-718
11. Myers MB, Kreis W (1976) Purification of deoxycytidine kinases from two P815 murine neoplasms and their separation from deoxyguanosine kinase. Arch Biochem Biophys 177:10-15
12. Xu YZ, Plunkett W (1992) Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,27prime;-difluorodeoxycytidine. Biochem Pharmacol 44:1819-1827
13. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826
14. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB (1991) Preclinical in vivo activity of 27prime;,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214
15. Kaye SB (1994) Gemcitabine: Current status of phase I and phase II trials. J Clin Oncol 12:1527-1531
16. Ruiz van Haperen VWT, Veerman G, Eriksson S, et al (1994) Development and molecular characterization of a 27prime;,27prime;-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138-4143
17. Abbruzzese JL, Grunewald R, Weeks EA, et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498
18. Grunewald R, Abbruzzese JL, Tarassoff P, et al (1991) Saturation of 27prime;,2′-difluorodeoxycytidine 57prime;-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262
19. Rosso R, Martin C (1994) Effect of patients age on gemcitabine toxicity profile and efficacy in advanced non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:366
20. Dunlop PJ, Cameron C, Dabouis G, et al (1994) Phase I dose escalation study of cisplatin in combination with gemcitabine in non-small cell lung cancer. Proc Am Soc Clin Oncol 13:342
21. Rodriguez GI, Drengler R, Burris HA, Rinaldi D, Hammond L, Kraynak M, Stephens S, Forral K, Voi M, Von Hoff DD (1997) A phase I study of gemcitabine in combination with hydroxyurea in patients with advanced solid tumors. Proc Am Soc Clin Oncol 16:207a
22. Guchelaar H-J, Richel DJ, van Knapen A (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15-31
23. Anderson H, Thatcher N, Walling J, et al (1994) A phase I study of 24 hour infusion of gemcitabine in patients with previously untreated, locally advanced, non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:348
24. Tempero M, Capadano M, Tarassoff P (1994) Dose escalation of gemcitabine in previously untreated patients with pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13:218
25. Grunewald R, Kantarjian H, Du M, et al (1992) Gemcitabine in leukemia; a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413
26. Pollera CF, Ceribelli A, Crecco M, et al (1994) Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184
27. Poplin EA, Corbett T, Flaterty L, et al (1992) Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study. Invest New Drugs 10:165-170
28. Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 [Suppl 9]:1-10
29. Donehower RC (1992) An overview of the clinical experience with hydroxyurea. Semin Oncol 19:11-20
30. Kennedy BJ (1992) The evolution of hydroxyurea therapy in chronic myelogenous leukemia. Semin Oncol 19:21-26
31. Kolitz JE, Kempin SJ, Schluger A, Wong GY, Berman E, Jhanwar S, Arlin ZA, Gee T, Clarkson BD (1992) A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia. Semin Oncol 19:27-33
32. Levin VA (1992) The place of hydroxyurea in the treatment of primary brain tumors. Semin Oncol 19:34-40
33. Kinsella TJ (1992) Radiosensitization and cell kinetics: Clinical implications for S phase-specific radiosensitizers. Semin Oncol 19:41-47
34. Stehman FB (1992) Experience with hydroxyurea as a radiosensitizer in carcinoma of the cervix. Semin Oncol 19:48-52
35. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 95465. J Clin Oncol 18:2780-2787
36. Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, Khayat D, Rivelles N (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase I pharmacokinetic trial. J Clin Oncol 18:2545-2552
37. Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA (2001) Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 48:95-103
38. 4PteGlu assays. Adv Exp Med Biol 244:97-106